Intellia Therapeutics Stock Performance
| NTLA Stock | USD 12.78 1.46 10.25% |
On a scale of 0 to 100, Intellia Therapeutics holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of 1.4, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intellia Therapeutics will likely underperform. Please check Intellia Therapeutics' skewness, day typical price, and the relationship between the downside variance and daily balance of power , to make a quick decision on whether Intellia Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Intellia Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain essential indicators, Intellia Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.56 | Five Day Return 17.88 | Year To Date Return 16.53 | Ten Year Return (35.57) | All Time Return (35.57) |
1 | Intellia Therapeutics Stock Price Up 4.1 percent Whats Next | 05/19/2025 |
2 | Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial NTLA | 05/29/2025 |
3 | Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635 | 06/05/2025 |
4 | Acquisition by Bhanji Muna of 11450 shares of Intellia Therapeutics at 8.37 subject to Rule 16b-3 | 06/13/2025 |
5 | Intellia Therapeutics, Inc. Backed by H.C. Wainwright for 237 percent Upside Potential | 06/17/2025 |
6 | Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress | 06/23/2025 |
7 | Disposition of 1547 shares by Goodman Jesse of Intellia Therapeutics at 9.56 subject to Rule 16b-3 | 06/30/2025 |
8 | Disposition of 1547 shares by Goodman Jesse of Intellia Therapeutics at 9.23 subject to Rule 16b-3 | 07/01/2025 |
9 | Disposition of 2503 shares by Michael Dube of Intellia Therapeutics at 9.95 subject to Rule 16b-3 | 07/02/2025 |
10 | Intellia Therapeutics, Inc. Director Jesse Goodman Sells 1,547 Shares of Stock | 07/03/2025 |
11 | Take the Zacks Approach to Beat the Markets Amarin, Mogo, 3M in Focus | 07/14/2025 |
12 | Lewis Asset Management LLC Sells 2,500 Shares of Intellia Therapeutics, Inc. | 07/21/2025 |
| Begin Period Cash Flow | 240.4 M | |
| Total Cashflows From Investing Activities | 125.6 M |
Intellia Therapeutics Relative Risk vs. Return Landscape
If you would invest 831.00 in Intellia Therapeutics on April 25, 2025 and sell it today you would earn a total of 524.00 from holding Intellia Therapeutics or generate 63.06% return on investment over 90 days. Intellia Therapeutics is currently generating 0.9626% in daily expected returns and assumes 5.763% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Intellia, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intellia Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intellia Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intellia Therapeutics, and traders can use it to determine the average amount a Intellia Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.167
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NTLA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.96 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Intellia Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intellia Therapeutics by adding it to a well-diversified portfolio.
Intellia Therapeutics Fundamentals Growth
Intellia Stock prices reflect investors' perceptions of the future prospects and financial health of Intellia Therapeutics, and Intellia Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intellia Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (7.27) % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 103.58 M | ||||
| Price To Earning | (19.91) X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 30.66 X | ||||
| Revenue | 57.88 M | ||||
| Gross Profit | (417.32 M) | ||||
| EBITDA | (523.98 M) | ||||
| Net Income | (519.02 M) | ||||
| Cash And Equivalents | 874.28 M | ||||
| Cash Per Share | 11.50 X | ||||
| Total Debt | 210.2 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.24 X | ||||
| Book Value Per Share | 7.53 X | ||||
| Cash Flow From Operations | (348.88 M) | ||||
| Earnings Per Share | (5.23) X | ||||
| Market Capitalization | 1.4 B | ||||
| Total Asset | 1.19 B | ||||
| Retained Earnings | (2.18 B) | ||||
| Working Capital | 529.01 M | ||||
| Current Asset | 77.63 M | ||||
| Current Liabilities | 10.7 M | ||||
About Intellia Therapeutics Performance
By analyzing Intellia Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Intellia Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Intellia Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intellia Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.8 K | -4 K | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.60) | (0.62) |
Things to note about Intellia Therapeutics performance evaluation
Checking the ongoing alerts about Intellia Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intellia Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intellia Therapeutics is way too risky over 90 days horizon | |
| Intellia Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 57.88 M. Net Loss for the year was (519.02 M) with loss before overhead, payroll, taxes, and interest of (417.32 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (348.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Lewis Asset Management LLC Sells 2,500 Shares of Intellia Therapeutics, Inc. |
- Analyzing Intellia Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intellia Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Intellia Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intellia Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intellia Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intellia Therapeutics' stock. These opinions can provide insight into Intellia Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |